These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38041877)

  • 1. Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance.
    Shen H; Zhu R; Liu Y; Hong Y; Ge J; Xuan J; Niu W; Yu X; Qin JJ; Li Q
    Drug Resist Updat; 2024 Jan; 72():101013. PubMed ID: 38041877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer.
    Tan G; Jin B; Qian X; Wang Y; Zhang G; Agyekum EA; Wang F; Shi L; Zhang Y; Mao Z; Shi C; Xu Y; Li X; Zhang L; Li S
    Sci Rep; 2024 Oct; 14(1):23719. PubMed ID: 39390090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomics reveals the implication of acetoacetate and ketogenic diet therapy in radioiodine-refractory differentiated thyroid carcinoma.
    Wang J; Xu Q; Xuan Z; Mao Y; Tang X; Yang K; Song F; Zhu X
    Oncologist; 2024 Sep; 29(9):e1120-e1131. PubMed ID: 38760956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.
    Silaghi H; Lozovanu V; Georgescu CE; Pop C; Nasui BA; Cătoi AF; Silaghi CA
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.
    Satapathy S; Bal C
    Front Endocrinol (Lausanne); 2022; 13():924841. PubMed ID: 35903277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer.
    Zhao S; Zhao Y; Zhao Y; Wang G
    Front Endocrinol (Lausanne); 2023; 14():1320044. PubMed ID: 38313845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.
    Zhang L; Li Z; Zhang M; Zou H; Bai Y; Liu Y; Lv J; Lv L; Liu P; Deng Z; Liu C
    Med Oncol; 2023 Jul; 40(9):258. PubMed ID: 37524925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.
    Liu Y; Wang J; Hu X; Pan Z; Xu T; Xu J; Jiang L; Huang P; Zhang Y; Ge M
    Drug Resist Updat; 2023 May; 68():100939. PubMed ID: 36806005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
    Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
    Liu J; Liu Y; Lin Y; Liang J
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake.
    Guo Y; Cai Y; Song F; Zhu L; Hu Y; Liu Y; Ma W; Ge J; Zeng Q; Ding L; Li L; Zheng G; Ge M
    Endocrine; 2023 Sep; 81(3):503-512. PubMed ID: 37020077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas.
    Li G; Lei J; Song L; Jiang K; Wei T; Li Z; Gong R; Zhu J
    Cancer Med; 2018 Nov; 7(11):5448-5456. PubMed ID: 30264548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
    Spitzweg C; Bible KC; Hofbauer LC; Morris JC
    Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
    Volpe F; Nappi C; Zampella E; Di Donna E; Maurea S; Cuocolo A; Klain M
    Curr Oncol; 2024 Jul; 31(7):3870-3884. PubMed ID: 39057158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
    Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
    Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing Radioiodine Incorporation in
    Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
    Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular basis and targeted therapies for radioiodine refractory thyroid cancer.
    Yu Q; Zhang X; Li L; Zhang C; Huang J; Huang W
    Asia Pac J Clin Oncol; 2023 Jun; 19(3):279-289. PubMed ID: 35950297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF
    de la Fouchardiere C; Alghuzlan A; Bardet S; Borget I; Borson Chazot F; Do Cao C; Godbert Y; Leenhardt L; Zerdoud S; Leboulleux S
    Bull Cancer; 2019 Sep; 106(9):812-819. PubMed ID: 31200896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
    Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
    Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.